global hepatitis drugs market is estimated to grow at a CAGR of 25.0%
during the forecast period 2022-2030.
identified as one of the principal causes of mortality across the globe. Close
to 0.8 million deaths are recorded every year due to complications arising from
hepatitis type B, whereas hepatitis C is held responsible for approximately 0.5
million mortality cases every year.
Hepatitis is an
inflammatory medical condition that affects the liver severely. The condition
can also affect the digestive system and brain of the individual up to serious
levels. It can either lead to acute,
semi-acute or chronic infection. The
most common hepatitis is viral hepatitis which can be caused by any of the five
hepatotropic viruses A, B, C, D, and E. However, there are three major
types of hepatitis conditions known - HAV, HBV, and HCV. Apart from bacterial
& viral infections, the condition
can be caused by autoimmune diseases, heavy alcohol consumption, toxins, and
certain prescription medications.
are available only for Hepatitis type A and Hepatitis type B viruses. However,
research into the development of vaccines for Hepatitis type C is under
incidences of different types of hepatitis cases across the world, the burgeoning
demand for drugs to treat and manage hepatitis cases, the surging awareness
among people, the growing geriatric population, the escalating healthcare
expenditure, and investments in the development of drugs and therapy for hepatitis
by public and private organizations and the growing number of new product
launches and regulatory approvals of hepatitis drugs by authorities are the
primary factors driving the growth of the global hepatitis drugs market.
Additionally, the emphasis of market players on research and development
activities for gaining approval for various clinical trials for future HCV and
HBV drugs to be commercially available in the market has been increasing
rapidly. Alongside, the introduction of new therapies in the market such as
that of interferon-free combination regimens and second generation DAAs which
are expected to attain higher SVR and cause lesser side effects than currently
are expected to bring about tremendous growth opportunities for the global
hepatitis market in the forthcoming years.
Moreover, the increasing number of promotional activities and funding by
market players and government associations to support the development of drug
therapies & diagnosis and also for providing tailor-made solutions to
patients is a major factor set to augment the growth of the market in the next
few years. Some of the major
organizations involved include Centers for Disease Control and Prevention
(CDC), American Liver Foundation, WHO, U.S. Department of Health and Human
Services (HHS), Immunization Action Coalition, and Hepatitis Foundation
factors such as the increasing number of collaborations and mergers &
acquisitions among the major market players for offering novel solutions to
treat hepatitis infections, the emerging trend of pediatric combination
vaccines which aid in the protection against multiple causative agents and the
growing launching of generic versions of existing brands are anticipated to
further fuel the growth of the global hepatitis drugs market during the
However, factors such as the high capital requirement for the manufacturing,
development, and commercialization of drugs indicated for the treatment of
hepatitis and the pro-longed development process and approval time of new pharmaceutical
drugs are projected to restrict the market's growth up to some extent during
the forecast period.
HEPATITIS DRUGS MARKET SEGMENTATION
By Drug Class
Nucleotide Polymerase / NS5A
Hepatitis C Protease / NS5A
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type
By Route of
Middle East and Africa
Based on disease type, the hepatitis C segment accounted for the largest market
share of 82.0% in the global hepatitis drugs market in 2021. The segment is
anticipated to retain its dominance in the market and witness the highest
growth rate in the market during the forecast period.
The North American
region held the most dominating position in the global hepatitis drugs market
in 2021, followed by Europe. The region is estimated to further retain its
dominance in the market over the forecast period. The growth of the market in
the region can be attributed to the growing number of initiatives and measures
taken up by the private organizations and governments to raise awareness and
prevent hepatitis infections in the region, the escalating investments in the
R&D to improve healthcare infrastructures in the region and the rising
healthcare expenditure in the region. The U.S. is the major contributor to the
growth of the market in the region.
The Asia Pacific region
is projected to emerge as the fastest-growing regional market for hepatitis
drugs globally during the forecast period due to factors such as the
proliferating prevalence rate of hepatitis in the region's major economies and
the burgeoning demand for generic drugs in the region. The major contributors
to the region include India and China.
The Middle East
and African region is also expected to hold a significant portion of the global
hepatitis drugs market during the forecast period due to the rising popularity
and usage of various HBV and HCV drugs in the region, especially in the parts
KEY COMPANIES IN HEPATITIS DRUGS MARKET
Dynavax Technologies Corporation
F. Hoffmann-La Roche Ltd.
Mitsubishi Tanabe Pharma Corporation
Bristol-Myers Squibb Company
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Vertex Pharmaceuticals Inc.
Hetero Healthcare Limited